Advancing Molecular Diagnostics for Earlier, More Reliable and More Precise Cancer Detection
I am Rukayat Olayemi Oni, MSc, MB(ASCP), an ASCP-certified Technologist in Molecular Biology specializing in Precision Molecular Oncology Diagnostics.
My work focuses on the application of advanced molecular technologies to cancer detection, disease monitoring, biomarker analysis, and high-complexity clinical diagnostics.
My professional experience spans personalized circulating tumor DNA (ctDNA) testing, Multi-Cancer Early Detection (MCED), colorectal cancer screening, genomic testing, molecular biomarker analysis, laboratory quality systems, and cancer research.
Through my work, research, and innovation, I seek to strengthen the reliability, efficiency, and clinical value of molecular diagnostics in modern cancer care.
MB(ASCP) Certified
Technologist in Molecular Biology, American Society for Clinical Pathology — specializing in Precision Molecular Oncology Diagnostics.
Science. Precision. Better Cancer Diagnostics.
I hold a Master of Science in Biology from Georgia State University, a Bachelor of Science in Cell Biology and Genetics from the University of Lagos, and a National Diploma in Science Laboratory & Technology from Yaba College of Technology.
I am certified by the American Society for Clinical Pathology (ASCP) as a Technologist in Molecular Biology.
My experience spans research and high-complexity clinical laboratory environments, where I have worked with molecular technologies including PCR, RT-qPCR, QuARTS, Next-Generation Sequencing, methylation-based biomarkers, genomic analysis, immunoassays, DNA extraction and amplification, automated laboratory systems, and quality-controlled diagnostic workflows.
My career has progressed from cancer research and diagnostics to colorectal cancer screening, Multi-Cancer Early Detection, and personalized ctDNA testing. This progression has shaped my specialization in Precision Molecular Oncology Diagnostics.
Master of Science in Biology
Georgia State University — graduate training strengthened my expertise in biological research, experimental methods, laboratory analysis, scientific interpretation, and research communication.
Bachelor of Science in Cell Biology and Genetics
University of Lagos — built my foundation in cellular biology, molecular genetics, laboratory science, and biological research.
National Diploma in Science Laboratory & Technology
Yaba College of Technology — provided my early technical foundation in laboratory science and scientific experimentation.
Technologist in Molecular Biology — MB(ASCP)
American Society for Clinical Pathology (ASCP)
Professional Member
American Society for Clinical Pathology
Professional Member
Association for Diagnostics & Laboratory Medicine (ADLM)
Precision Molecular Oncology Diagnostics
Precision Molecular Oncology Diagnostics combines molecular biology, genomic technologies, cancer biomarkers, clinical laboratory science, and quality-driven diagnostic systems to improve cancer detection and monitoring.
The increasing ability to detect cancer-associated molecular signals creates significant opportunities for earlier detection and more personalized disease monitoring. My contribution is focused on helping translate these sophisticated molecular technologies into reliable, reproducible, and scalable diagnostic practice.
- Molecular cancer detection and monitoring
- Circulating tumor DNA (ctDNA)
- Multi-Cancer Early Detection
- Molecular biomarkers
- Colorectal cancer screening
- Genomic oncology
- PCR and Next-Generation Sequencing
- Assay reliability and quality control
- Molecular laboratory optimization
- Precision oncology
ONCODIAX™
ONCODIAX™ is my landmark innovation in Precision Molecular Oncology Diagnostics. I developed ONCODIAX™ to address a fundamental challenge in modern molecular laboratories: advanced diagnostic technologies generate substantial specimen, molecular, assay, quality-control, and workflow information, but these elements are often evaluated independently rather than as part of an integrated diagnostic-intelligence system. ONCODIAX™ brings these components together.
It is a structured framework designed to help molecular oncology laboratories evaluate diagnostic readiness, strengthen assay reliability, identify workflow inefficiencies, and measure laboratory performance.
Molecular Diagnostic Intelligence
Evaluates specimen integrity, molecular information, pre-analytical quality, process traceability, and testing readiness through the Molecular Diagnostic Intelligence Index (MDII™).
Biomarker & Assay Reliability
Identifies patterns that may affect analytical reliability through the Biomarker & Assay Reliability Score (BARS™).
Molecular Laboratory Workflow
Identifies testing bottlenecks, repeat processes, resource constraints, and workflow inefficiencies through the Molecular Workflow Optimization Matrix (MWOM™).
Diagnostic Performance
Connects laboratory interventions with measurable quality and performance indicators through the Diagnostic Performance & Reliability Index (DPRI™).
Together, these components provide a unified architecture for improving molecular oncology diagnostic operations.
The framework produces a Molecular Diagnostic Readiness Score (MDRS™) that assesses laboratory maturity across:
ONCODIAX™ can support molecular oncology laboratories, cancer-screening programs, genomic testing environments, diagnostic companies, biotechnology organizations, and clinical research laboratories.
Impact Across the Molecular Testing Continuum
Advancing Cancer Diagnostics Across the Molecular Testing Continuum
Within Natera's Signatera unit, I perform advanced molecular diagnostic testing supporting personalized circulating tumor DNA (ctDNA) analysis for cancer monitoring.
My responsibilities include DNA extraction, purification, amplification, molecular analysis, quality control, assay and instrument-output evaluation, troubleshooting, SOP improvement, personnel training, and continuous laboratory process improvement.
This work places me at the intersection of molecular technology and personalized cancer monitoring.
As a Clinical Laboratory Scientist II, I worked within Multi-Cancer Early Detection (MCED), performing advanced biomarker assays involving plasma-derived samples, methylation-sensitive PCR and high-throughput proteomic technologies.
My work included assay and workflow validation, QA/QC, User Acceptance Testing, process improvement, and cross-functional collaboration.
I also contributed to activities associated with the Falcon Real-World Evidence registry, involving more than 25,000 participants undergoing annual MCED testing.
My earlier work at Exact Sciences focused on molecular screening for colorectal cancer and advanced adenomas.
I worked with multi-target stool DNA technology, QuARTS, methylated DNA biomarkers including NDRG4 and BMP3, KRAS mutations, beta-actin reference measurement, PCR-based detection, and protein biomarker testing.
This experience strengthened my understanding of how multiple molecular and biochemical signals can be integrated into clinically useful cancer-screening systems.
My cancer diagnostics foundation includes experience with PCR, multiplex qPCR, Next-Generation Sequencing, immunoassays, tumor biomarkers, and molecular analysis of genes including BRCA1/2, KRAS and EGFR.
I also participated in analytical workflow development and validation, clinical trial sample processing, therapeutic drug monitoring, and multidisciplinary cancer-management activities.
Connecting Molecular Research with Diagnostic Innovation
Research remains an important component of my professional development. At Georgia State University, I worked as a Research Assistant conducting molecular biology and microbiological laboratory research, experimental data analysis, sample preparation, serological assays, bioassays, and technical reporting.
I also contributed to an NSF-funded project examining evidence-based biology teaching practices and presented findings at the Georgia State University Research Conference.
Recent Developments in the Significant Effect of mRNA Modification (M6A) in Glioblastoma and Esophageal Cancer
This publication examines the emerging significance of m6A RNA modification in cancer biology, including glioblastoma and esophageal cancer.
Vegetation Analysis of Herbaceous Species in the University of Lagos, Nigeria
Molecular Technologies & Laboratory Systems
Molecular Diagnostics
PCR, RT-qPCR, QuARTS, Next-Generation Sequencing, Genomics, DNA Extraction, Molecular Amplification, ELISA, Western Blot, Molecular Biomarkers, Mammalian Cell Culture
Cancer Diagnostics
ctDNA, Multi-Cancer Early Detection, Colorectal Cancer Screening, Methylation Biomarkers, KRAS, BRCA1/2, EGFR, Tumor Biomarkers, Precision Oncology
Laboratory Quality
CLIA, CAP, GLP, GMP, Quality Control, Quality Assurance, SOPs, Data Integrity, Assay Workflows, Laboratory Safety
Analytics & Lab Systems
LIMS, SPSS, JMP, GraphPad, R Statistics, Laboratory Automation, Data Interpretation, Technical Reporting
Extending Impact Beyond the Bench
My professional contribution extends beyond laboratory testing. These experiences reinforce my commitment to advancing molecular diagnostics through both technical practice and knowledge transfer.
Laboratory Mentorship
I have trained and mentored laboratory professionals on specialized instrumentation, testing protocols, standard workflows, troubleshooting, and quality practices.
Academic Instruction
During my time at Georgia State University, I also instructed and mentored more than 100 undergraduate students per semester in biological laboratory techniques, scientific analysis, experimental troubleshooting, and interpretation of laboratory results.
Building the Next Generation of Molecular Cancer Diagnostics
The future of cancer diagnostics will increasingly depend on our ability to identify meaningful molecular signals earlier, analyze them accurately, and translate them into reliable information for clinical care.
My professional vision is to contribute to this evolution by advancing Precision Molecular Oncology Diagnostics through scientific research, laboratory innovation, molecular technologies, quality-driven testing, and diagnostic-intelligence systems.
ONCODIAX™ represents an important part of this vision. By connecting molecular diagnostic intelligence, assay reliability, laboratory workflow, and measurable performance, I aim to contribute toward cancer diagnostic systems that are increasingly precise, reliable, scalable, and clinically meaningful.
Connect With Rukayat
I welcome opportunities for scientific collaboration, molecular diagnostics research, professional engagement, peer review, speaking, and partnerships relating to precision oncology and cancer diagnostics.